Disappointingly, after thousands of clinical trials of tumor vaccines in a variety of tumor types, only sipuleucel, a tumor vaccine loaded with the prostatic acid phosphatase (PAP) antigen and GM-CSF showed moderate efficacy and was approved by the FDA to treat asymptomatic or mildly symptomatic hormone-refractory prostate cancer. This evidence concerns the gene ACP3 and neoplasm.